FDA approves Roche’s RozlytrekTM (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Anil Bhaskar
Unified Customer Experience

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Laura Blair
Medication Adherence

Frank X. Powers
Healthcare Challenger Brands

Stacey Gandler
Brand Nourishment

Thomas Shea
Programmatic Marketing

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

David Linetsky
Patient Activation

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Mike Viscel
Increasing Engagement

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs